Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | $959 | — | $2,877 |
| Operating expenses: | ||||
| Research and development | 36,226 | 30,227 | 68,547 | 69,001 |
| General and administrative | 10,511 | 13,219 | 17,861 | 21,171 |
| Change in fair value of contingent consideration | 8,733 | (566) | 8,842 | (6,214) |
| Total operating expenses | 55,470 | 42,880 | 95,250 | 83,958 |
| Operating loss | (55,470) | (41,921) | (95,250) | (81,081) |
| Other income (expense), net: |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's G&A?
- Odyssey Therapeutics (ODTX) reported G&A of $10.51M in Q2 2026.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Odyssey Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude